Engineering in Precision Medicine
工程技术助力精准医疗
Ali Khademhosseini
ABSRACT
Engineered materials that integrate advances in polymer chemistry, nanotechnology, and biological sciences have the potential to create powerful medical therapies. Dr. Khademhosseini’s group is interested in developing ‘personalized’ solutions that utilize micro- and nanoscale technolgoies to enable a range of therapies for organ failure, cardiovascular disease and cancer. In enabling this vision he works closely with clinicians (including interventional radiologists, cardiologists and surgeons). He has developed numerous techniques in controlling the behavior of patient-derived cells to engineer artificial tissues and cell-based therapies. His group also aims to engineer tissue regenerative therapeutics using water-containing polymer networks called hydrogels that can regulate cell behavior. Specifically, he has developed photo-crosslinkable hybrid hydrogels that combine natural biomolecules with nanoparticles to regulate the chemical, biological, mechanical and electrical properties of gels. These functional scaffolds induce the differentiation of stem cells to desired cell types and direct the formation of vascularized heart or bone tissues. Since tissue function is highly dependent on architecture, he has used microfabrication methods, such as microfluidics, photolithography, bioprinting, and molding, to regulate the architecture of these materials. He has employed these strategies to generate miniaturized tissues. It is anticipated that such approaches will lead to the development of next-generation regenerative therapeutics and biomedical devices.
整合了高分子科学，纳米技术，以及生物技术的生物材料有潜力来实现很多生物医疗应用。Khademhosseini教授的实验室致力于开发基于微制备及纳米技术的“个性化”疗法，例如治疗器官退化、心脑血管疾病、以及癌症。他与临床医生紧密合作来推进这个愿景，包括介入放射科医生，心血管病医生，以及外科医生。他开发了多种技术来改造病人细胞来做人工组织或者细胞疗法。他的课题组同时也开发组织再生疗法，比如说使用水凝胶网络来控制细胞的行为。他开发了一个可光交联的复合水凝胶，并在其中整合了生物大分子、纳米粒子来调控水凝胶的化学，生物学，力学，及电学性质。这些水凝胶能够促进干细胞分化成目标细胞，并直接形成血管化的心肌组织以及骨组织。因为组织的功能高度取决于它的结构，他还医用微制备技术来控制生物材料的结构，包括微流控、光刻、生物打印、和模具成型。他用这些技术制造了很多微型组织。这些技术有望引领下一代再生疗法和生物医疗装置。
BIOGRAPHY
Ali Khademhosseini is currently the CEO and Founding Director at the Terasaki Institute for Biomedical Innovation. Previously, he was a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He joined UCLA as the Levi Knight Chair in November 2017 from Harvard University where he was Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Center a leading initiative in making engineered biomedical materials. Dr. Khademhosseini is an Associate Editor for ACS Nano. He is a fellow of the American Institute of Medical and Biological Engineering, Biomedical Engineering Society, Royal Society of Chemistry, Biomaterials Science and Engineering, Materials Research Society, and American Association for the Advancement of Science. He is a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada and Canadian Academy of Engineering. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.
Ali Khademhosseini 目前是Terasaki Institute for Biomedical Innovation的创始主任兼首席执行官。在此之前，他是加州大学洛杉矶分校（UCLA）生物工程系，化学工程系，以及放射学系的Levi Knight 讲席教授。并担任微创诊疗中心主任。他曾是哈佛大学医学院（HMS）和哈佛-麻省理工医疗科技学院（HST）终身教授，并兼职于著名的布莱根妇女医院（BWH）和Wyss研究所。 在哈佛大学，他领导创建了哈佛大学生物材料创新研究中心（BIRC）。Khademhosseini博士是ACS Nano的副主编。他拥有麻省理工学院生物工程博士学位 （2005），以及多伦多大学化学工程硕士学位（2001）和本科学位（1999）。